key: cord-0852901-wj4symwk authors: Mayo, MacKenzie; Potugari, Bindu; Bzeih, Rami; Scheidel, Caleb; Carrera, Carolyn; Shellenberger, Richard A. title: Cancer screening during the COVID-19 pandemic: A systematic review and meta-analysis. date: 2021-10-18 journal: Mayo Clin Proc Innov Qual Outcomes DOI: 10.1016/j.mayocpiqo.2021.10.003 sha: 77feee907a8688ed89c284f82c04d5af50c39bab doc_id: 852901 cord_uid: wj4symwk Objective To assess the impact of measures designed to mitigate the spread of COVID-19 on worldwide cancer screening. Patient and Methods We systematically searched PubMed.gov, Ovid Medline, the Cochrane COVID-19 study register, ClinicalTrials.gov, and Embase without language restrictions for studies published between January 1, 2021 and February 10, 2021. Studies were selected for full text review which contained data on patients screened for any type of cancer during the COVID-19 pandemic and comparison data from a time interval just prior to the pandemic. Data was obtained through dual extraction. All the included studies were assessed for quality and risk of bias. A meta-analysis was performed on 13 studies: seven on screening mammography; five on colon cancer screening, and three on cervical cancer screening. The screening outcomes were reported as pooled incidence rates ratios using the inverse variance method and random effects models. All studies included in our meta-analysis reported the number of patients screened for cancer in defined time intervals before and during the COVID-19 pandemic. Results Incidence rate ratios (IRRs) were significantly lower for screening during the COVID-19 pandemic for breast cancer (0.63, 95% CI=.53,.77, P=<.001), colon cancer (0.11, 95% CI=.05,.24, P=<.001), and cervical cancer (0.10, 95% CI =.04,.24,P=< 0.001). Conclusion We found moderate level evidence showing significant decreases in cancer screening for breast, colon, and cervical cancers during the COVID-19 pandemic, which may add further morbidity and mortality to this public health crisis. P=<.001), colon cancer (0.11, 95% CI=.05,. 24 Modelling studies predict increased rates of tumor upstaging as well as higher disease specific morbidity and mortality due to decreased and delayed cancer screening in 2020. 6, 7 The aim of our systematic review was to examine the impact the COVID-19 pandemic has had on worldwide cancer screening or secondary prevention. We began our systematic review by writing a study question and protocol Our database search and study selection process are outlined in the flow diagram ( Figure 1 ). We identified 748 articles for our systematic review with 113 identified as eligible for full-text review. Eleven of these studies met our inclusion criteria and provided the numbers of patients screened before and after lockdown measures were instituted. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] These studies met inclusion criteria for our meta-analysis with their characteristics described in Table 1 . [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] We five studies which examined colon cancer screening, seven studies for breast cancer screening, and three for cervical cancer screening in our statistical analysis (Table 1 ). There were two of our studies which reported on more than one type of cancer screening. 12, 14 The result of pooling studies that tracked breast cancer screening before and during the COVID-19 pandemic found a significantly lower rate of breast cancer screening during the pandemic compared to before with a Results of leave-one-out influence analyses showed that the significance of the pooled estimate does not change after omitting any of the studies. Since there were only two studies devoted to the evaluation of lung cancer screening during the COVID-19 pandemic, we were unable to perform a meta-analysis on these data. 13, 6, 17, 25, 28 One study used data from insurance company claims for screening procedures. 18 Notably, the reported decreases in cancer screening rates were consistently large within each cancer type; the range in the decline of screening mammography rates was 51-77%, screening colonoscopies fell by 1-55%, and cervical cancer screening was 5-18% of the pre-COVID-19 pandemic rates. The consistency of these results is support for generalizability of our findings across various healthcare settings. Limitations to our study are reflective of our study design. Our study question could only be answered by collecting and analyzing data from retrospective observational studies of cohorts of patients or data collection from patient registries. Since all of the studies were retrospective and unblinded, the potential exists for a risk of bias in the assessment of outcomes and data reporting (Table 2 ). However, since the outcomes are highly objective, we assess the risk of reporting or selection bias to be low. None of the studies included a method for ensuring any patients were not counted more than once in the data registries. The certainly of evidence was evaluated with the GRADE approach for all three of our studied outcomes. 10 Using this approach, we determined the quality of evidence to be high for diminished colon cancer screening and moderate for the diminution of breast and cervical cancer screening during the beginning of the COVID-19 pandemic. We reviewed several studies which reported only the rates in which cancer screening was reduced during the pandemic. 7, [24] [25] [26] [27] [28] [29] [30] Without data on the numbers of patients screened we were unable to include these studies in our statistical analysis. In an attempt to collect more data we contacted the corresponding authors of these studies twice and received data from only one, which became an included study. 21 Bias due to J o u r n a l P r e -p r o o f confounding seems unlikely in our studies, although covariate analysis was not performed in any of our included studies and an inference cannot be made regarding screening disparities (Table 2) . Including data from an insurance registry is a potential confounder for two of our included studies. 12, 21 The short time period of diminished screening for cancer during the COVID-19 pandemic lock-down periods has unclear long-term implications. In conclusion, we found high quality evidence for diminished screening Legends for Tables: Table 1 . Study characteristics Table 2 . Quality assessment and risk of bias J o u r n a l P r e -p r o o f Table 2 . Modified Newcastle-Ottawa quality assessment score a Study Selection Comparability Outcome Representativeness of exposed cohort Ascertainment of exposure Challine, 2021 11 1 1 1 1 Gorin, 2021 12 1 1 0 1 Latinga, 2021 13 1 1 0 1 Mantellini, 2020 14 1 1 1 1 Sutherland, 2020 15 1 1 0 1 Chou, 2020 16 1 1 0 1 Tsai HJ, 2020 17 1 1 1 1 J o u r n a l P r e -p r o o f Song, 2020 18 1 1 1 1 Tsai HY, 2020 19 1 1 1 1 Chiriac, 2021 20 1 1 1 1 Miller, 2021 21 1 1 0 1 a) A score of 1 is equal to 1 star and signifies a low risk of bias J o u r n a l P r e -p r o o f Association of Stay-at-Home Orders With COVID-19 Hospitalizations in 4 States Comparison of Estimated Rates of Coronavirus Disease 2019 (COVID-19) in Border Counties in Iowa Without a Stay-at-Home Order and Border Counties in Illinois With a Stay-at-Home Order Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US Non-Emergent Impact of SARS-CoV-2 Pandemic on Colorectal Cancer Screening Delay: Effect on Stage Shift and Increased Mortality. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Effective Heathcare Programs. Assessing the Risk of Bias of Individual Studies in Sytematic Reviews of Haelth Care Interventios Clinical Practice Guidelines: A Primer on Development and Dissemination Colorectal screening: We have not caught up. A surge of colorectal cancer after the coronavirus disease 2019 (COVID-19) pandemic? Surgery The future of cancer screening after COVID-19 may be at home Impact of the COVID-19 pandemic on gastrointestinal endoscopy in the Netherlands: analysis of a prospective endoscopy database Oncological organized screening programmes in the COVID-19 era: an Italian survey on accrued delays, reboot velocity, and diagnostic delay estimates Impact of COVID-19 on healthcare activity in NSW, Australia. Public health research & practice Impact of the COVID-19 pandemic on the volume of mammography examinations in Southern Taiwan The feasibility and necessity of cancer screening events in the community during the COVID-19 pandemic in Taiwan Disruptions in preventive care: Mammograms during the COVID-19 pandemic. Health services research Effects of the COVID-19 pandemic on breast cancer screening in Taiwan The Impact of the COVID-19 Pandemic on Gastrointestinal Endoscopy Activity in a Tertiary Care Center from Northeastern Romania Impact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21-65 Years in a Large Integrated Health Care System -Southern California Patterns and Trends in Cancer Screening in the United States Preventing Breast, Cervical, and Colorectal Cancer Deaths: Assessing the Impact of Increased Screening The Impact of the Coronavirus Disease-19 Pandemic on Access to Endoscopy Procedures in the VA Healthcare System Operational Challenges of a Low-Dose CT Lung Cancer Screening Program During the Coronavirus Disease Impact of the COVID-19 pandemic on a population-based breast cancer screening program Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors Colorectal Cancer Screening and COVID-19. The American journal of gastroenterology The number of obstructive colorectal cancers in Japan has increased during the COVID-19 pandemic: A retrospective single-center cohort study. Annals of medicine and surgery Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic None